Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Omeprazole and Dasatinib (SPRYCEL) in Healthy Adults
NCT06145217Phase 1Completed
- Sponsor
- Xspray Pharma
- Start
- Aug 2023
- Primary completion
- Aug 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasatinib in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), sponsored by Xspray Pharma. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the Last Quantifiable Concentration. Started Aug 2023; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06145217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145217.